Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block] Accrued Expenses and Other Liabilities Accounts Payable Current Accounts payable Accounts Receivable Net Current Accounts receivable Accretion Amortization Of Discounts And Premiums Investments Accretion of premiums and discounts on investments Accrued Liabilities And Other Liabilities Accrued expenses and other liabilities Accrued expenses and other liabilities Accrued Professional Fees Current Accrued professional fees and other Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive income Additional Paid In Capital Additional paid-in capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: Amended agreement. Amended Agreement [Member] Amendment to GSK Agreement [Member] Amendment Flag Amendment Flag Amortization Of Debt Discount Premium Amortization of discount on loan payable Amortization Of Financing Costs Amortization of deferred financing costs Amortization Of Lease Incentives Amortization of deferred lease incentive Annual Base Rent Future Minimum Payments Year Four Annual Base Rent Future Minimum Payments Year Four Base rent, year four Annual Base Rent Future Minimum Payments Year One Annual Base Rent Future Minimum Payments Year One Base rent, year one Annual Base Rent Future Minimum Payments Year Three Annual Base Rent Future Minimum Payments Year Three Base rent, year three Annual Base Rent Future Minimum Payments Year Two Annual Base Rent Future Minimum Payments Year Two Base rent, year two Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Common stock equivalents excluded from computation of earning per share Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Name [Domain] Antidilutive Securities, Name [Domain] Area Of Leased Office And Laboratory Space Area Of Leased Office And Laboratory Space Area of leased office and laboratory space Assets Total assets Assets [Abstract] Assets Assets Current Total current assets Assets Current [Abstract] Current assets: Assets Fair Value Disclosure Financial assets at fair value Available For Sale Securities Investments, available for sale Available For Sale Securities Amortized Cost Investments, Amortized cost Available For Sale Securities Current Investments, available for sale Investments, Fair value Available For Sale Securities Gross Unrealized Gain Accumulated In Investment Available For Sale Securities Gross Unrealized Gain Accumulated In Investment Investments, Unrealized gains Available For Sale Securities Gross Unrealized Losses Accumulated In Investment Available For Sale Securities Gross Unrealized Losses Accumulated In Investment Investments, Unrealized losses Avanir pharmaceuticals. Avanir Pharmaceuticals [Member] Avanir Pharmaceuticals [Member] Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Basis Of Presentation And Significant Accounting Policies [Text Block] Basis of Presentation and Significant Accounting Policies Cash And Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Cash And Cash Equivalents At Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash And Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash And Cash Equivalents Fair Value Disclosure Cash and cash equivalents, Fair value Cash And Cash Equivalents Period Increase Decrease Net increase in cash and cash equivalents Cash Cash Equivalents And Short Term Investments [Text Block] Cash, Cash Equivalents and Investments, Available for Sale Cash [Member] Cash [Member] Celgene. Celgene [Member] Celgene [Member] Class Of Stock [Domain] Class of Stock [Domain] Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Warrants to purchase shares of common stock, exercise price per share Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Common stock warrant issued upon on conversion of preferred stock Collaborative Arrangement Disclosure [Text Block] Collaborations Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Commitments And Contingencies Commitments Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $0.001 par value per share; 100,000,000 and 83,716,667 shares authorized, 18,013,810 and 1,298,300 shares issued and outstanding in 2014 and 2013, respectively Contracts Receivable Claims And Uncertain Amounts Eligible Payments receivable Conversion Of Stock [Line Items] Conversion of Stock [Line Items] Conversion Of Stock Shares Converted 1 Number of stock converted Conversion Of Stock [Table] Conversion of Stock [Table] Counterparty Name [Axis] Counterparty Name [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Loan Payable Debt Instrument Basis Spread On Variable Rate 1 Debt instrument, variable rate Debt Instrument Description Of Variable Rate Basis Debt instrument, description of interest rate Debt Instrument Interest Rate During Period Debt instrument, annum interest rate Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument Maturity Date Range End 1 Debt instrument maturity date, end date Debt Instrument Maturity Date Range Start 1 Debt instrument maturity date, start date Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Deferred Rent Credit Current Deferred rent, current portion Deferred Rent Credit Noncurrent Deferred rent, net of current portion Deferred Revenue Deferred revenue Deferred Revenue Additions Deferred revenue, payment received Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Domain] Deferred Revenue [Domain] Deferred Revenue Current Deferred revenue, current portion Deferred Revenue Noncurrent Deferred revenue, net of current portion Deferred Revenue Recognition Period Deferred Revenue Recognition Period Arrangement consideration allocated to the License Deliverable, recognition period Depreciation And Amortization Depreciation and amortization Derivative Liabilities Noncurrent Warrant to purchase redeemable securities Development based milestones. Development Based Milestones [Member] Development Milestone [Member] Development Services [Member] Development Services [Member] Development Support Services [Member] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] Earnings Per Share [Abstract] Earnings Per Share Basic And Diluted Basic and diluted income (loss) per share allocable to common stockholders Net (loss) income per share applicable to common stockholders-basic and diluted Earnings Per Share [Text Block] Earnings (Loss) Per Share Employee Related Liabilities Current Employee compensation and benefits Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1 Total unrecognized compensation cost related to unvested options, weighted-average recognition period Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Total unrecognized compensation cost related to unvested options Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Expansion Of Office And Laboratory Space Expansion Of Office And Laboratory Space Expansion of premises Fair Value Adjustment Of Warrants Re-measurement of warrant to purchase redeemable securities Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Assets Measured On Recurring Basis [Text Block] Financial Assets Recognized at Fair Value Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class [Domain] Fair Value Assumptions Expected Term Investments, Average maturity Fair Value By Asset Class [Axis] Asset Class [Axis] Fair Value By Fair Value Hierarchy Level [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value Inputs Level 1 [Member] Level 1 [Member] Fair Value Inputs Level 2 [Member] Level 2 [Member] Fair Value Inputs Level 3 [Member] Level 3 [Member] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings Increase in fair value recognized in net loss Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements Reclassification to additional paid-in capital in connection with IPO Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value Ending Balance Beginning Balance Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation Table [Text Block] Schedule of Activity in Preferred Stock Warrant Liability First discount deliverable. First Discount Deliverable [Member] First Discount Deliverable [Member] First tranche. First Tranche [Member] First Tranche [Member] Gain Loss On Sale Of Securities Net Realized gains or losses on sales of investments General And Administrative Expense General and administrative General And Administrative Expense [Member] General and Administrative [Member] Gsk. Gsk [Member] GSK [Member] Impairment Of Investments Other than temporary impairment losses, investments Incentive From Lessor Deferred lease incentive, net of current portion Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Tax Expense Benefit Income tax provisions or benefits Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Accrued Interest Receivable Net Interest receivable Increase Decrease In Accrued Liabilities And Other Operating Liabilities Accrued expenses and other liabilities Increase Decrease In Deferred Liabilities Deferred rent Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase Decrease In Other Operating Assets Other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Initial program. Initial Program [Member] Initial Program [Member] Interest Paid Cash paid for interest Interest Receivable Interest receivable Investment Income Dividend Investment income I P O [Member] IPO [Member] Jazz pharmaceuticals. Jazz Pharmaceuticals [Member] Jazz Pharmaceuticals [Member] Joint steering committee deliverable. Joint Steering Committee Deliverable [Member] Joint Steering Committee Deliverable [Member] Lease Beginning Date Lease Beginning Date Lease extension, beginning date Lease Beginning Date On Additional Space Lease Beginning Date On Additional Space Lease on additional space, beginning date Lease Expiry Date On Additional Space Lease Expiry Date On Additional Space Lease additional space, expiry date Lease Extension Periods Lease Extension Periods Lease extension period Leasehold Improvements Gross Allowance on general improvements Lease Incentive Payable Current Deferred lease incentive, current portion Letters Of Credit Outstanding Amount Letter of credit delivered under lease Liabilities Total liabilities Liabilities And Stockholders Equity Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Liabilities And Stockholders Equity [Abstract] Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Liabilities Assumed 1 Initial public offering costs incurred but unpaid at period end Liabilities Current Total current liabilities Liabilities Current [Abstract] Current liabilities: License Agreement Expiry Period License Agreement Expiry Period Expiry period of license exercise fee License And Services Revenue License and research and development revenue License deliverable. License Deliverable [Member] License Deliverable [Member] Licensed. Licensed [Member] Licensed products [Member] License exercise fee. License Exercise Fee [Member] License Exercise Fee [Member] Line Of Credit Facility Maximum Borrowing Capacity Aggregate advance provided under the Agreement Loans Payable Current Loan payable, net of discount Long Term Debt Maturities Repayments Of Principal In Next Twelve Months Aggregate Future minimum payments due under the Loan and Security Agreement for the remainder of 2015 Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year Aggregate Future minimum payments due under the Loan and Security Agreement for the remainder of 2014 Longterm Debt Type [Axis] Long-term Debt, Type [Axis] Longterm Debt Type [Domain] Long-term Debt, Type [Domain] Long Term Loans Payable Loan payable, net of current portion and discount Major Property Class [Axis] Major Property Class [Axis] Major Property Class [Domain] Major Property Class [Domain] Maximum [Member] Maximum [Member] Milestone scenario one. Milestone Scenario One [Member] If Celgene Exercises its Rights With Respect to Either of the Two Additional License Programs [Member] Milestone scenario two. Milestone Scenario Two [Member] If Celgene Exercises its Option With Respect to the Option Program [Member] Minimum [Member] Minimum [Member] Money Market Funds [Member] Money Market Funds Included in Cash Equivalents [Member] Nature Of Business [Line Items] Nature Of Business [Line Items] Nature Of Business [Line Items] Nature Of Business [Table] Nature Of Business [Table] Nature Of Business [Table] Nature Of Operations Nature of Business Net Cash Provided By Used In Financing Activities Net cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities [Abstract] Financing activities Net Cash Provided By Used In Investing Activities Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities [Abstract] Investing activities Net Cash Provided By Used In Operating Activities Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities [Abstract] Operating activities Net Income Loss Net (loss) income Net (loss) income Net income (loss) Net Income Loss Available To Common Stockholders Basic Net (loss) income applicable to common stockholders-basic and diluted Net (loss) income applicable to common stockholders-basic and diluted Net Income Loss Available To Common Stockholders Basic [Abstract] Reconciliation of net (loss) income to net (loss) income applicable to common stockholders: New Accounting Pronouncements Policy Policy [Text Block] Recent Accounting Pronouncements Number Of Additional License Programs Granted Number Of Additional License Programs Granted Number of additional license program Number Of Equal Monthly Installments Number Of Equal Monthly Installments Debt instrument, number of equal monthly installments Number Of Options Choice Programs Offered Number Of Options Choice Programs Offered Number of options for providing license program Number Of Tranches Number Of Tranches Number of tranches One Twenty Eight Spring Street Lexington Limited Liability Company [Member] One Twenty Eight Spring Street Lexington Limited Liability Company [Member] 128 Spring Street Lexington LLC [Member] Operating Cash Flows Direct Method [Abstract] Operating Cash Flows, Direct Method [Abstract] Operating Expenses Total operating expenses Operating Expenses [Abstract] Operating expenses: Operating Income Loss (Loss) Income from operations Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Other additional license program. Other Additional License Program [Member] One of the Additional License Programs [Member] Other Assets Noncurrent Other assets Other Comprehensive Income Loss Net Of Tax Comprehensive (loss) income Other Comprehensive Income Loss Tax [Abstract] Other comprehensive (loss) income: Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Unrealized gain (loss) on investments Other Liabilities Current Research and development expenses Other Loans Payable Current Leasehold improvement loan, current portion Other Loans Payable Long Term Leasehold improvement loan, net of current portion Other Nonoperating Income Expense Interest and other expense Outstanding Leasehold Improvement Loan Outstanding Leasehold Improvement Loan Outstanding leasehold improvement loan Patent support deliverable. Patent Support Deliverable [Member] Patent Support Deliverable [Member] Payables And Accruals [Abstract] Payables and Accruals [Abstract] Payments Of Debt Issuance Costs Loan issuance cost paid to lenders Payments Of Stock Issuance Costs Payment of initial public offering costs Payments To Acquire Investments Purchases of investments Payments To Acquire Property Plant And Equipment Purchases of property and equipment Percentage of royalty on net sales. Percentage Of Royalty On Net Sales Percentage of royalty on net sales required to pay under the agreement Phase one clinical trial. Phase One Clinical Trial [Member] Phase One Clinical Trial [Member] Phase two or three clinical trial. Phase Two Or Three Clinical Trial [Member] Phase 2 or Phase 3 clinical trial [Member] Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock Value Preferred stock, $0.001 par value per share: 5,000,000 shares authorized, no shares issued and outstanding Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Prime Rate [Member] Prime Rate [Member] Proceeds From Issuance Initial Public Offering Net proceeds of IPO Proceeds from initial public offering, net of underwriting discounts and commissions Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock Proceeds From Issuance Of Debt Advance made under the tranche Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities Maturities of investments Property Plant And Equipment Net Property and equipment, net Range [Axis] Range [Axis] Range [Member] Range [Domain] Redeemable Convertible Preferred Stock [Member] Redeemable Convertible Preferred Stock [Member] Regulatory milestones. Regulatory Milestones [Member] Regulatory Milestones [Member] Reimbursements of travel and intellectual property expenses. Reimbursements Of Travel And Intellectual Property Expenses [Member] Reimbursements of Travel and Intellectual Property Expenses [Member] Repayments Of Long Term Debt Principal payments on loan payable Repayments Of Other Long Term Debt Repayment of leasehold improvement loan Repurchase Agreement Counterparty Name [Domain] Counterparty Name [Domain] Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research And Development Arrangement Contract To Perform For Others Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research And Development Expense Research and development Research And Development Expense [Member] Research and Development [Member] Research and development services deliverable. Research And Development Services Deliverable [Member] R&D Services Deliverable [Member] Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member] Restricted Cash and Cash Equivalents [member] Restricted Cash And Cash Equivalents Noncurrent Restricted cash Retained Earnings Accumulated Deficit Accumulated deficit Revenue Recognition Milestone Method Revenue Recognized Milestone revenue Revenue recognized Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Amount Allocated arrangement consideration Revenues Total revenue Revenues [Abstract] Revenue: Royalty Term Royalty Term Royalty term Sale Of Stock Name Of Transaction [Domain] Sale of Stock, Name of Transaction [Domain] Sales based milestones. Sales Based Milestones [Member] Sales-based Milestone [Member] Scenario Unspecified [Domain] Scenario, Unspecified [Domain] Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Accrued Expenses and Other Liabilities Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Common Stock Equivalents Excluded from Calculation of Diluted Loss Per Share Schedule Of Cash Cash Equivalents And Short Term Investments Table [Text Block] Cash, Cash Equivalents and Investments, Available for Sale Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Computation of Basic and Diluted Earnings (Loss) Per Share Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Stock-Based Compensation Expense Related to All Stock Based Awards Recognized in Statements of Operations and Comprehensive Income (Loss) Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Stock Option Activity Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Estimated Weighted-Average Assumptions of Options Granted Second discount deliverable. Second Discount Deliverable [Member] Second Discount Deliverable [Member] Second tranche. Second Tranche [Member] Second Tranche [Member] Series C preferred stock warrants. Series C Preferred Stock Warrants [Member] Series C Preferred Stock Warrants [Member] Share Based Compensation Stock-based compensation expense Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected dividend yield Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1 Expected lives Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Weighted Average Remaining Contractual Term (Years) Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value 1 Aggregate Intrinsic Value, Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Exercisable Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term 1 Exercisable Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Intrinsic value of stock options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Forfeited or expired Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Forfeited or expired Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Stock options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Weighted-average fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Aggregate Intrinsic Value, Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Outstanding ending balance Outstanding beginning balance Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward] Number of options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Outstanding ending balance Outstanding at beginning of year Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Weighted average exercise price per share Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2 Outstanding Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value Aggregate Intrinsic Value, Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Vested and expected to vest Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price Vested and expected to vest Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term 1 Vested and expected to vest Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value 1 Total grant date fair value of stock options that vested during the period Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Estimated Forfeiture Rate Used In Determining Amount Of Stock Based Compensation Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Estimated Forfeiture Rate Used In Determining Amount Of Stock Based Compensation Estimated forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Description And Terms Share based compensation expiration terms for grant and vested option Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Granted Shares Issued Price Per Share Common stock price per share Statement Class Of Stock [Axis] Class of Stock [Axis] Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement Scenario [Axis] Scenario [Axis] Stockholders Equity Total stockholders' equity (deficit) Stockholders Equity [Abstract] Stockholders' equity (deficit): Stockholders Equity Note Stock Split Conversion Ratio 1 Reverse stock split of common stock, ratio Stock Issued During Period Shares Conversion Of Convertible Securities Conversion of preferred stock into shares of common stock Stock Issued During Period Shares New Issues Common stock, issued Stock Issued During Period Shares Stock Options Exercised Exercised Stock Option [Member] Outstanding Stock Options [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Subsequent Event [Member] Subsequent Event [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Event Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsidiary Sale Of Stock [Axis] Subsidiary, Sale of Stock [Axis] Supplemental Cash Flow Information [Abstract] Supplemental cash flow information: Supply deliverable. Supply Deliverable [Member] Supply Deliverable [Member] Temporary Equity Accretion To Redemption Value Adjustment Accretion on redeemable convertible preferred stock Less: accretion of redeemable convertible preferred stock to redemption value Temporary Equity Carrying Amount Attributable To Parent Redeemable convertible preferred stock, $0.001 par value per share; 0 and 62,916,667 shares (Series A, B, C, D) authorized, respectively; no shares and 56,047,067 shares issued and outstanding, in 2014 and 2013 respectively Temporary Equity Par Or Stated Value Per Share Redeemable convertible preferred stock (Series A, B, C, D), par value Temporary Equity Shares Authorized Redeemable convertible preferred stock (Series A, B, C, D), shares authorized Temporary Equity Shares Issued Redeemable convertible preferred stock (Series A, B, C, D), shares issued Temporary Equity Shares Outstanding Redeemable convertible preferred stock (Series A, B, C, D), shares outstanding Trading Symbol Trading Symbol Transaction [Domain] Transaction [Domain] Transaction Type [Axis] Transaction Type [Axis] Undistributed Earnings Allocated To Participating Securities Undistributed earnings applicable to participating preferred shareholders Undistributed earnings applicable to participating preferred stockholders Up Front Payment Arrangement [Member] Non-refundable Up-front Payment Arrangement [Member] Use of Estimates and Summary of Significant Accounting Policies [Policy Text Block] Use Of Estimates And Summary Of Significant Accounting Policies Policy [Text Block] Use of Estimates and Summary of Significant Accounting Policies U S Government Agencies Debt Securities [Member] Government Agency Securities [Member] U S Treasury Securities [Member] U.S. Treasury Obligation [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Warrant [Member] Warrant [Member] Weighted Average Number Of Diluted Shares Outstanding Weighted-average number of common shares used in net (loss) income per share applicable to common stockholders-diluted Weighted-average shares outstanding - diluted Weighted Average Number Of Shares Outstanding Basic Weighted-average number of common shares used in net (loss) income per share applicable to common stockholders-basic Weighted-average shares outstanding - basic